Docosahexaenoic acid sensitizes leukemia lymphocytes to barasertib and everolimus by ros-dependent mechanism without affecting the level of ros and viability of normal lymphocytes

Anticancer Research

Volumn 36, Issue 4, 2016, Pages 1673-1682

  Zhelev, Zhivko ^a,b   Ivanova, Donika ^a   Lazarova, Desislava ^c   Aoki, Ichio ^d   Bakalova, Rumiana ^c,d   Saga, Tsuneo ^d  

^a TRAKIA UNIVERSITY   (Bulgaria)

^b INSTITUTE OF BIOPHYSICS AND BIOMEDICAL ENGINEERING   (Bulgaria)

^c UNIVERSITY OF SOFIA   (Bulgaria)

^d NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Barasertib; DHA; Docosahexaenoic acid; Everolimus; Leukemia lymphocytes; Reactive oxygen species

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; BARASERTIB; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BLEOMYCIN; BORTEZOMIB; CARBONYL DERIVATIVE; CISPLATIN; DOCOSAHEXAENOIC ACID; DOXORUBICIN; EVEROLIMUS; IXAZOMIB; LOMUSTINE; LONAFARNIB; PALBOCICLIB; PROTEIN; PROTEIN CARBONYL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; ANTINEOPLASTIC AGENT; ORGANOPHOSPHATE; QUINAZOLINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; HUMAN; HUMAN CELL; JURKAT CELL LINE; LEUKEMIA CELL; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN CARBONYLATION; CELL SURVIVAL; DRUG EFFECTS; LEUKEMIA; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOCOSAHEXAENOIC ACIDS; EVEROLIMUS; HUMANS; JURKAT CELLS; LEUKEMIA; LYMPHOCYTES; ORGANOPHOSPHATES; QUINAZOLINES; REACTIVE OXYGEN SPECIES;

EID: 84983006822     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Fetterman JW Jr. and Zdanowicz MM: Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 66: 1169-1179, 2009.
2. Saravanan P, Davidson NC, Schmidt EB and Calder PC: Cardiovascular effects of marine omega-3 fatty acids. Lancet 376: 540-550, 2010.
3. Swanson D, Block R and Mousa SA: Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr 3: 1-7, 2012.
4. Julia V, Macia L and Dombrowicz D: The impact of diet on asthma and allergic diseases. Nat Rev Immunol 15: 308-322, 2015.
5. Wysocza?ski T, Soko?a-Wysocza?ska E, P?kala J, Lochy?ski S, Czy? K, Bodkowski R, Herbinger G, Patkowska-Soko?a B and Librowski T: Omega-3 fatty acids and their role in the central nervous system-a review. Curr Med Chem 2016 doi: 10.2174/0929867323666160122114439.
6. Karmali RA, Marsh J and Fuchs C: Effect of n-3 fatty acids on growth of a rat mammary tumor. J Natl Cancer Inst 73: 457-461, 1984.
7. Gonzalez MJ, Schemmel RA, Gray JI, Dugan LJr, Sheffield LG and Welsch CW: Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in a thymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. Carcinogenesis 12: 1231-1235, 1991.
8. Xia S, Lu Y, Wang J, He C, Hong S, Serhan CN and Kang JX: Melanoma growth is reduced in Fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Nalt Acad Sci USA 103: 12499-12504, 2006.
9. Jia Q, Lupton JR, Smith R, Weeks BR, Callaway E, Kang LA, McMurray DN and Chapkin RS: Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice. Cancer Res 68: 3985-3991, 2008.
10. Siddique RA, Harvey KA, Walker C, Altenburg J, Xu Z, Terry C, Camarillo I, Jones-Hall Y and Mariash C: Characterization of synergistic anticancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorogenesis in mice. BMC Cancer 13: 418, 2013.
11. Zou S, Meng X, Meng Y, Liu J, Liu B, Zhang S, Ding W, Wu J and Zhiu J: Microarray analysis of anticancer effects of docosahexaenoic acid on human colon cancer model in nude mice. Int J Clin Exp Med 8: 5075-5084, 2015.
12. Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, Castella B, Gazzano E, Ghigo D, Rizzo AM and Riganti C: Omega 3 fatty acids chemosensitize multidrug/resistant colon cancer cells by down-regulation cholesterol synthesis and altering detergent-resistant membrane composition. Mol Cancer 12: 137, 2013.
13. Fahrmann JF and Hardman WE: Omega 3 fatty acids increase chemosensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anticancer drugs doxorubicin, vincristine and fludarabine. Lipids Health Dis 12: 36, 2013.
14. Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ and Bellet RE: Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol 63: 451-458, 2009.
15. Anel A, Naval J, Desportes J, Gonzalez B, Uriel J and Pineiro A: Increased cytotoxicity of polyunsaturated fatty acids on human tumoral B and T-cell lines compared with normal lymphocytes. Leukemia 6: 680-688, 1992.
16. Hsu HC, Chen CY and Chen MF: n-3 Polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes-involvement of uncoupling protein UCP2. J Biomed Sci 21: 101, 2014.
17. Abdi J, Garssen J, Faber J and Redegeld FA: Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells, but not in normal peripheral mononuclear cells. J Nutr Biochem 25: 1254-1262, 2014.
18. Hidaka A, Shimazu T, Sawada N, Yamaji T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S and Japan Public Health Center-based Prospective Study Group: Fish, n-3 PUFA consumption and pancreatic cancer risk in Japanese: a large, population-based, prospective cohort study. Am J Clin Nutr 102: 1490-1497, 2015.
19. Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazi T, Yamaji T, Takachi R, Tanaka Y, Mizokami M, Tsugane S and Japan Public Health Center-based Prospective Study Group: Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 142: 1468-1475, 2012.
20. Chan SS, Luben R, Olsen A, Tjonneland A, Kaaks R, Lindgren S, Grip O, Bergmann MM, Boeing H, Hallmans G, Karling P, Overvad K, Venø SK, van Schaik F, Bueno-de-Mesquita B, Oldenburg B, Khaw KT, Riboli E and Hart AR: Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease. Aliment Pharmacol Ther 39: 834-842, 2014.
21. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C and Floch OL: Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 101: 1978-1985, 2009.
22. Merendino N, Costantini L, Manzi L, Molinari R, D'Eliseo D and Velotti F: Dietary 3 polyunsaturated fatty acid DHA: A potential adjuvant in the treatment of cancer. BioMed Res Int, Article ID 310186, 2013.
23. Gleissmann H, Johnsen I and Kogner P: Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res 316: 1365-1373, 2010.
24. Siddiqui RA, Harvey K and Stillwell W: Anticancer properties of oxidation products of docosahexaenoic acid. Chem Phys Lipids 153: 47-56, 2008.
25. Trombetta A, Maggiora M, Martinasso G, Cotogni P, Canuto RA and Muzio G: Archidonic and docosahexaenoic acids reduce the growth of A549 human lung tumor cells increasing lipid peroxidation and PPARs. Chem Biol Interact 165: 239-250, 2007.
26. Ding WQ, Vaught JL, Yamauchi H and Lind SE: Differential sensitivity of cancer cells to docosahexaenoic acid-induced cytotoxicity: the potential importance of down-regulation of superoxide dismutase 1 expression. Mol Cancer Ther 3: 1109-1117, 2004.
27. Tuller ER, Beavers CT, Nitchel JR, Ihnat A, Benbriik MD and Ding WQ: Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cencer cells: the involment of peroxisome proliferator-activated receptor ? and hypoxiainducible factor-2? signaling. Mol Pharmacol 76: 588-595, 2009.
28. Diep QN, Touyz RM and Schiffrin EL: Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 36: 851-855, 2000.
29. Manzi L, Costantini L, Molinari R and Merendino N: Effect of dietary w-3 polyunsaturated fatty acid DHA on glycolytic enzymes and Warburg phenotypes in cancer. Biomed Res Int, Article ID 137097, 2015.
30. Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, Berry D, Steward W and Dennison A: The effect of omega-3 FAs on tumor angiogenesis and their therapeutic potential. Eur J Cancer 45: 2077-2086, 2009.
31. Jakobsen CH, Storvold GL, Bremseth H, Follestad T, Sand K, Mack M, Olsen KS, Lundemo AG, Iversen JG, Krokan HE and Schonberg SA: DHA induced ER stress and growth arrest in human colon cancer cells: associations with cholesterol and calcium homeostasis. J Lipid Res 49: 2089-2100, 2008.
32. Kolar SS, Barhoumi R, Callaway ES, Fan YY, Wang N, Lupton JR and Chapkin RS: Synergy between docosahexaenoic acid and butyrate elicits p53-independent apoptosis via mitochondrial Ca2+ accumulation in colonocytes. Am J Physiol Gastrointest Liver Physiol 293: G935-G943, 2007.
33. Kolar SS, Barhoumi R, Lupton JR and Chapkin RS: Docosahexaenoic acid and butyrate synergistically induce colonocyte apoptosis by enhancing mitochondrial Ca2+ accumulation. Cancer Res 67: 5561-5568, 2007.
34. Schroder M and Kaufman RJ: Endoplasmic reticulum stress and the unfolded protein response. Mutat Res 569: 29-63, 2005.
35. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
36. Ozben T: Oxidative stress and apoptosis: impact of cancer therapy. J Pharm Sci 96: 2181-2196, 2007.
37. De Larco J, Park CA, Dronava H and Furcht LT: Paradoxical roles for antioxidants in tumor prevention and eradication. Cancer Biol Ther 9: 362-370, 2010.
38. Ivanova D, Bakalova R, Lazarova D, Gadjeva V and Zhelev Z: The impact of reactive oxygen species on anticancer therapeutic strategies. Adv Clin Exp Med 22: 899-908, 2013.
39. Yasueda A, Urushima H and Ito T: Efficacy and interaction of antioxidant supplements as adjuvant therapy in cancer treatment: A systematic review. Integr Cancer Ther 15: 17-39, 2016.
40. Larsson SC, Kumlin M, Ingelman-Sundberg M and Wolk A: Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79: 935-945, 2004.
41. Pardini RS: Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents. Chem Biol Interact 162: 89-105, 2006.
42. Chapkin RS, McMurray DN and Lupton JR: Colon cancer, fatty acids and anti-inflammatory compounds. Curr Opin Gastroenterol 23: 48-54, 2007.
43. Berquin IM, Edwards IJ and Chen YQ: Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Letters 269: 363-377, 2008.
44. Colas S, Maheo K, Denis F, Goupille C, Hoinard C, Champeroux P, Tranquart F and Bougnoux P: Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. Clin Cancer Res 12: 5879-5886, 2006.
45. Hardman WE, Avula CP, Fernandes G and Cameron IL: Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res 7: 2041-2049, 2001.
46. Wang Z, Butt K, Wang L and Liu H: The effect of seal oil on paclitaxel-induced cytotoxicity and apoptosis in breast carcinoma MCF-7 and MDA-MB-231 cell lines. Nutr Cancer 58: 230-238, 2007.
47. Maheo K, Vibet S, Steghensb JP, Dartigeasa C, Lehmana M, Bougnoux P and Gore J: Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med 39: 742-751, 2005.
48. Vibet S, Goupille C, Bougnoux P, Steghens JP, Gore J and Maheo K. Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 44: 1483-1491, 2008.
49. Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P and Johnsen JI: Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenicinduced oxidative stress. Int J Cancer 118: 2584-2593, 2006.
50. Rudra PK and Krokan HE: Cell-specific enhancement of doxorubicin toxicity in human tumour cells by docosahexaenoic acid. Anticancer Res 21: 29-38, 2001.
51. Gleissman H1, Yang R, Martinod K, Lindskog M, Serhan CN, Johnsen JI and Kogner P: Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J 24: 906-915, 2010.
52. Gleissman H, Segerström L, Hamberg M, Ponthan F, Lindskog M, Johnsen JI and Kogner P: Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo. Int J Cancer 128: 1703-1711, 2011.
53. Pettersen K, Monsen VT, Hakvag-Pettersen CH, Overland HB, Pettersen G, Samdal H, Tesfahun AN, Lundemo AG, Bjorkoy G and Schonberg SA: DHA-induced stress response in human colon cancer cells-focus on oxidative stress and autophagy. Free Radic Biol Med 90: 158-172, 2016.
54. Lin H, Hou CC, Cheng CF, Chiu TH, Hsu YH, Sue YM, Chen TH, Hou HH, Chao YC, Cheng TH and Chen CH: Peroxisomal proliferator-activated receptor-alpha protects renal tubular cells from doxorubicin-induced apoptosis. Mol Pharmacol 72: 1238-1245, 2007.
55. Zhelev Z, Ivanova D, Aoki I, Saga T and Bakalova R: 2-Deoxy-D-glucose sensitizes cancer cells to Barasertib and Everolimus by ROS-independent mechanism(s). Anticancer Res 35: 6623-6632, 2015.
56. Dimri M, Bommi PV, Sahasrabuddhe AA, Khandekar JD and Dimri GP: Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis 31: 489-495, 2010.